Vistagen Therapeutics Inc
NASDAQ:VTGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vistagen Therapeutics Inc
NASDAQ:VTGN
|
US |
Intrinsic Value
The intrinsic value of Vistagen Therapeutics Inc (VTGN) under the Base Case is 0.19 USD per share. Compared with the current market price of 0.18 USD, the stock appears Undervalued by 7% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Vistagen Therapeutics Does
VistaGen Therapeutics is a biopharmaceutical company that develops prescription medicines for mental health disorders, with a focus on conditions such as anxiety, depression, and related central nervous system diseases. It does not sell consumer products; instead, it works on drug candidates that are designed to be tested in clinical studies and, if successful, approved for use by doctors and patients.
- Headquarters
- United States of America US
- Employees
- 59
- IPO date
- Oct 18, 2010
Revenue & Expenses Breakdown
Vistagen Therapeutics Inc
Earnings Waterfall
Vistagen Therapeutics Inc
The intrinsic value for Vistagen Therapeutics Inc (VTGN) under the Base Case is 0.19 USD.
Compared with the current market price of 0.18 USD, the stock appears Undervalued by 7% .